Organon & Co. (OGN) Projected to Post Earnings on Thursday

Organon & Co. (NYSE:OGN) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.92 per share and revenue of $1.53 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Up 3.8 %

Shares of NYSE:OGN opened at $13.21 on Wednesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52-week low of $10.45 and a 52-week high of $23.10. The business’s 50 day simple moving average is $13.76 and its two-hundred day simple moving average is $15.09. The firm has a market cap of $3.41 billion, a P/E ratio of 3.97, a PEG ratio of 0.90 and a beta of 0.73.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 8.48%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s payout ratio is presently 33.63%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Morgan Stanley dropped their target price on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Organon & Co. currently has a consensus rating of “Hold” and an average target price of $19.75.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.